AusperBio Therapeutics Completes $37 Million Series A Financing Round
| | |

AusperBio Therapeutics Completes $37 Million Series A Financing Round

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (AusperBio) is a clinicalstage biotechnology company dedicated to advancing targeted oligonucleotide therapies. The company aims to achieve a functional cure for chronic hepatitis B (CHB) infection. The recently completed $37 million Series A financing round will support the clinical development of AusperBios lead product candidate, AHB137. Additionally,…

Merck Completes Acquisition of EyeBio for the Development of Restoret™
| | |

Merck Completes Acquisition of EyeBio for the Development of Restoret™

Merck, also known as MSD, has successfully completed the acquisition of EyeBio, a leading biotech company. The acquisition adds EyeBios promising candidate, Restoret™ (EYE103), to Mercks latestage pipeline for the treatment of retinal diseases. Restoret is an investigational tetravalent, trispecific antibody designed to target the Wnt signaling pathway, with positive results from the Phase 1b/2a…

Spotlight Medical Raises €6.2 Million Seed Funding Round led by Kurma Partners and Heal Capital
| | | |

Spotlight Medical Raises €6.2 Million Seed Funding Round led by Kurma Partners and Heal Capital

Spotlight Medical, a precision medicine company founded in 2024, has secured €6.2 million in a seed funding round to support the development of AIdriven prognosis tests for cancer patients. This funding will enable Spotlight Medical to bring its first prognosis test to the clinic, furthering its mission to provide personalized and effective care for cancer…

Granza Bio Secures $7.14M Seed Funding for Novel Therapeutic Delivery Platform
| | | |

Granza Bio Secures $7.14M Seed Funding for Novel Therapeutic Delivery Platform

Granza Bio, a biotechnology company founded in 2024 by a team of cancer and immunology researchers at the University of Oxford, has announced the successful close of its oversubscribed $7.14M Seed funding round. The company is focused on developing a novel delivery platform that leverages the discovery of the immune systems attack particles to combat…

Genexine Announces Merger with EPD Bio to Strengthen Drug Pipeline
| | | |

Genexine Announces Merger with EPD Bio to Strengthen Drug Pipeline

Genexine, a clinicalstage Korean biopharmaceutical company, has announced a merger with EPD Bio, a company specializing in targeted protein degradation technology. The merger aims to enhance Genexines drug pipeline by incorporating EPD Bios innovative bioPROTAC platform technology. The merger will bring together Genexines clinical and CMC development capabilities with EPD Bios expertise in PROTAC technology….

Radionetics Oncology Announces Strategic Relationship with Eli Lilly and Company
| | | | |

Radionetics Oncology Announces Strategic Relationship with Eli Lilly and Company

Radionetics Oncology, a biotechnology company specializing in developing small molecule radiopharmaceuticals targeting G protein coupled receptors (GPCRs) for solid tumor treatment, has formed a strategic relationship with Eli Lilly and Company. The agreement includes an upfront cash payment of $140 million to Radionetics, with an option for Lilly to acquire Radionetics for $1 billion after…

Kintara Therapeutics and TuHURA Biosciences Provide Corporate Updates and Outline NearTerm Milestones
| | |

Kintara Therapeutics and TuHURA Biosciences Provide Corporate Updates and Outline NearTerm Milestones

Kintara Therapeutics, Inc. and TuHURA Biosciences, Inc. provided an overview of their recent corporate and clinical advancements. Kintara focuses on developing new solid tumor cancer therapies, while TuHURA is an immuneoncology company working on technologies to overcome resistance to cancer immunotherapy. Recent Corporate Achievements: Kintara and TuHURA entered into a definitive merger agreement for a…

DiaMedica Therapeutics Inc. Closes $11.8 Million Private Placement
| | | |

DiaMedica Therapeutics Inc. Closes $11.8 Million Private Placement

DiaMedica Therapeutics Inc., a clinicalstage biopharmaceutical company focused on developing treatments for severe ischemic disease, recently closed a $11.8 million private placement to accredited investors. The funding will be utilized to support the companys ongoing clinical trials and expansion efforts in acute ischemic stroke and preeclampsia. The funding round was led by Thomas von Koch…

Genezen Acquires uniQures Commercial Gene Therapy Operations
| | | |

Genezen Acquires uniQures Commercial Gene Therapy Operations

Genezen, a leading gene therapy CDMO, has announced the acquisition of uniQures commercial gene therapy operations in Lexington, MA. This strategic move will allow Genezen to expand its services globally, providing latephase and commercial gene therapy development and manufacturing services. The acquisition includes a stateoftheart viral vector manufacturing facility and a highly skilled team from…

Kanvas Biosciences Raises $12.5 Million in Funding for Spatial Biology Platform
| | |

Kanvas Biosciences Raises $12.5 Million in Funding for Spatial Biology Platform

Kanvas Biosciences, a spatial biology company, has secured $12.5 million in additional funding to further develop its proprietary mapping technology and advance two novel therapeutics in its Immunooncology Program. The funding round was coled by existing investors DCVC and Lions Capital LLC, with participation from FemHealth Ventures, Germin8, Ki Tua Fund, and Pangaea Ventures. Paul…